Boots' Manoplax (flosequinan)
Executive Summary
Will be reviewed as a treatment for congestive heart failure by FDA's Cardiovascular & Renal Drugs Advisory Committee on Oct. 24, the first day of a two-day meeting. The Manoplax NDA (#19-960) has been pending since Sept. 28, 1990. . . .